Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome

被引:42
|
作者
Kaushik, Shalini V. [1 ,2 ]
Plaisance, Eric P. [2 ,3 ]
Kim, Teayoun [1 ,2 ]
Huang, Edmond Y. [1 ,2 ]
Mahurin, A. Jack [5 ]
Grandjean, Peter W. [2 ,4 ]
Mathews, Suresh T. [1 ,2 ]
机构
[1] Auburn Univ, Dept Nutr & Food Sci, Auburn, AL 36849 USA
[2] Auburn Univ, Boshell Diabet & Metab Dis Res Program, Auburn, AL 36849 USA
[3] Auburn Univ, Dept Anat Physiol & Pharmacol, Auburn, AL 36849 USA
[4] Auburn Univ, Dept Kinesiol, Auburn, AL 36849 USA
[5] Baptist Family Med Residency Program, Montgomery, AL 36116 USA
关键词
fetuin-A; niacin; Niaspan; alpha 2-HS glycoprotein; metabolic syndrome; triglycerides; MOLECULAR-WEIGHT ADIPONECTIN; RECEPTOR TYROSINE KINASE; INSULIN-RESISTANCE; NICOTINIC-ACID; INFLAMMATORY MARKERS; MEDIA THICKNESS; PLASMA; ASSOCIATION; INHIBITOR; GENE;
D O I
10.1002/dmrr.967
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Fetuin-A, a liver-secreted phosphoprotein and physiological inhibitor of insulin receptor tyrosine kinase, is associated with insulin resistance, metabolic syndrome (MetS), and an increased risk for type 2 diabetes. However, studies on the modulation of circulating levels of fetuin-A are limited. The goal of this study was to determine the effect of niacin administration on serum total- and phosphorylated fetuin-A (phosphofetuin-A) concentrations in individuals with MetS and correlate with changes in serum lipids, insulin sensitivity, and markers of inflammation. Methods Fifteen sedentary, obese, male participants, who met the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria for MetS, were treated with extended-release niacin (Niaspan) for 6 weeks. Blood samples were obtained before and after treatment with niacin. Results Serum fetuin-A and phosphofetuin-A concentrations were decreased following niacin administration (p < 0.005). Changes in fetuin-A concentrations were correlated with changes in triglyceride (r = 0.62, p = 0.01) and C-reactive protein (CRP) concentrations (r = 0.58, p, < 0.05) after nacin treatment. Changes in high-density lipoproteins (HDL)-cholesterol following niacin intervention were negatively correlated with changes in serum fetuin-A (p < 0.05) and phosphofetuin-A concentrations (p < 0.05). Serum cortisol levels were significantly elevated after niacin administration. Conclusions Niacin treatment lowers serum total- and phosphofetuin-A concentrations in individuals with MetS, and these changes correlate with the beneficial changes in serum lipids. Because niacin is known to induce insulin resistance, these findings suggest that fetuin-A may not be a mediator of niacin-induced insulin resistance but it may blunt the insulin resistance induced by niacin by decreasing its circulating concentrations. Copyright (c) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:427 / 434
页数:8
相关论文
共 50 条
  • [21] Serum fetuin-A in metabolic and inflammatory pathways in patients with myocardial infarction
    Voeroes, Krisztian
    Graf, Laszlo, Jr.
    Prohaszka, Zoltan
    Graf, Laszlo
    Szenthe, Peter
    Kaszas, Edit
    Boeroecz, Zoltan
    Cseh, Karoly
    Kalabay, Laszlo
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2011, 41 (07) : 703 - 709
  • [22] Use of extended-release niacin in clinical practice
    Suryadevara, Ramya S.
    Karas, Richard H.
    Kuvin, Jeffrey T.
    FUTURE LIPIDOLOGY, 2008, 3 (01): : 9 - 16
  • [23] Extended-Release Niacin (Nicotinic Acid)/Laropiprant
    Perry, Caroline M.
    DRUGS, 2009, 69 (12) : 1665 - 1679
  • [24] Utilization patterns of extended-release niacin in Canada: Analysis of an administrative claims database
    Dorais, Marc
    Chirovsky, Diana
    Ambegaonkar, Baishali
    Sazonov, Vasilisa
    Davies, Glenn
    Grant, Susan
    LeLorier, Jacques
    CANADIAN JOURNAL OF CARDIOLOGY, 2010, 26 (07) : E229 - E235
  • [25] A comparison of the pharmacokinetics of two different formulations of extended-release niacin
    Lauring, B.
    Rosko, K.
    Luo, W. -L.
    Wenning, L.
    Kissling, J.
    Roupe, K.
    Paolini, J. F.
    Wagner, J.
    Lai, E.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (01) : 15 - 22
  • [26] Serum fetuin-A concentrations are positively associated with serum VEGF levels in patients with newly diagnosed type 2 diabetes
    Zhou, Zhongwei
    Ju, Huixiang
    Sun, Mingzhong
    Chen, Hongmei
    Ji, Hongbin
    Jiang, Dongmei
    Ji, Yuqiao
    Ji, Jianwei
    ENDOCRINE JOURNAL, 2015, 62 (10) : 879 - 885
  • [27] Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin
    LaFleur, Joanne
    Thompson, Clinton J.
    Joish, Vijay N.
    Charland, Scott L.
    Oderda, Gary M.
    Brixner, Diana I.
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (7-8) : 1274 - 1279
  • [28] Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia
    Ballantyne, Christie
    Gleim, Gilbert
    Liu, Nancy
    Sisk, Christine McCrary
    Johnson-Levonas, Amy O.
    Mitchel, Yale
    JOURNAL OF CLINICAL LIPIDOLOGY, 2012, 6 (03) : 235 - 243
  • [29] Responses of Blood Lipids and Lipoproteins to Extended-Release Niacin and Exercise in Sedentary Postmenopausal Women
    Koh, Yunsuk
    Ben-Ezra, Vic
    Biggerstaff, Kyle D.
    Nichols, David L.
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2010, 65 (09): : 924 - 932
  • [30] Clinical and Biochemical Parameters in Relation to Serum Fetuin-A Levels in Overweight and Obese with and without Metabolic Syndrome in the Northeastern States of Indian Population
    Eswar, Sruti
    Rajagopalan, Balaji
    Ete, Kenyi
    Gattem, Srinivasa Nageswara Rao
    JMA JOURNAL, 2024, 7 (04): : 529 - 535